1. BY ALI LORD AND GARD HERLOFSEN
KRABBE’S DISEASE
BY ALI LORD AND GARD HERLOFSEN

2. WHAT IS KRABBE’S DISEASE?
Krabbe’s disease (globoid cell leukodystrophy) is a degenerative disorder that affects the nervous system.
It’s hereditary autosomal recessive disease.
Occurrence of 1 in 100,000 newborns.
It affects the myelin sheath of the nervous system.
Knud Haraldsen Krabbe.

3. HOW IS KRABBE DISEASE CAUSED?
Mutations in the GALC gene, causing deficiency of enzyme galactosylceramidase.
This effects the growth and maintenance of myelin, which causes severe degeneration of motor skills.
Krabbe disease is a leukodystrophy.
Fig.1 – www1.

4. DIAGNOSIS AND SYMPTOMS
Differential diagnosis by presence of multinucleated globoid cells.
Histological staining by Luxol blue for myelin.
Symptoms it causes are neurological.
Fever, Muscle weakness and Stiffness.
Type 1 - the infantile form is the most common,

5. Three stages -:
Stage 1: 3 – 6 months, stops developing, becomes irritable and has high muscle tone, trouble feeding.
Stage 2: Rapid nerve cell damage, leading to loss of use of muscles, damage to vision, seizures.
Stage 3: Blindness, deafness, fixed in a stiff posture. Lifespan in Type 1 is 13 months.
Type 2, 3, and 4. Do not survive beyond two years, but in Types 3 and 4 may vary.

6. MRI Scans revealing formation of myelin
Fig.4 – www2

7. PATHOLOGY Central Nervous System
Rare autosomal recessive disease  deficiency of GALC enzyme.
GALC  liposomal hydrolysis of galactolipids formed during myelination
Pathological changes in CNS/PNS  toxic, accumulated psychosine
Cannot be degraded  deficiency of GALC
Major changes: demyelination of fibers, reduction of oligondendroglia cells

8. TREATMENT No cure. Physical Therapy. Bone marrow transplant.
Cord Blood Transplant.

9. PROGNOSIS
High fatality rate in infants – generally occuring before the age of 2.
Late-onset of disease in patients live significantly longer due to slower progression.
Despite no cure, treatments specifically a marrow or blood cord transplants, have been effective in the early course of the disease.

10. CONCLUSION
Affects infants between the ages of 0-2 years and has a very high risk of fatality .
Higher prevalence in Scandinavian countries (1 in 50,000).
It is caused by the shortage of enzyme galactosylceramidase , effecting the myelin sheath of the nervous system.
No cure but methods are being developed.

11. References
Rosenberg.R, Dimauro.S, Paulson.H, Ptacek.L and Nestler.E (2008). The molecular and genetic basis of neurological and psychiatric disease. 4th ed. Philadelphia: Lipincotts Williams and Wilkins
Goldman.S, Schanz.S and Windrem.M.. (2008). Division of Cell and Gene Therapy and Center for Translational Neuromedicine. Stem cell-based strategies for treating pediatric disorders of myelin.. 17 (1),
www1 –
www2 –
www3-
www4-